Alnylam Pharmaceuticals Inc. (A1LN34)
Market Closed
12 Jun, 19:55
B3 B3 Primary R$
72. 52
0
0%
R$
193.27B Market Cap
- P/E Ratio
- Div Yield
4,923 Volume
-3.56 Eps
R$ 72.52
Previous Close Want to track A1LN34 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Alnylam Pharmaceuticals Inc. (A1LN34) Statistics
Valuation metrics
Market Cap 193.27B
Enterprise value 48.29B
Trailing P/E (ttm) 71.66
Forward P/E -
PEG ratio -0.16
Price/Sales (ttm) 45.08
Price/Book (mrq) 35.87
Enterprise Value/Revenue 2.25
Enterprise Value/EBITDA 11.93
Overview
Shares outstanding 133.44M
Float 132.96M
Shares short -
% Held by insiders -
% Held by institutions -
Average volume (10 days) 425
Average volume (90 days) 331
Price summary
52-Week low 71.96
52-Week high 132.4
Beta 0.3
50-Day moving average 80.85
200-Day moving average 104.35
Financials
Fiscal year
Fiscal year ends 31 Dec 2025
Most recent quarter (mrq) 31 Mar 2026
Profitability
Profit margin 0.13%
Operating margin 0.23%
Operational effectiveness
Return on assets 0.1%
Return on equity 0.9%
Income Statement
Revenue (ttm) 21.51B
Revenue per share (ttm) 1.63
Quarterly revenue growth (yoy) 0.96%
Gross profit (ttm) 17.38B
EBITDA 909.4M
Net income to common (ttm) 2.7B
Diluted EPS (ttm) 1.01
Quarterly earnings growth (yoy) 0.96%
Balance Sheet
Total cash (mrq) 15.1B
Total cash per share (mrq) 22.54
Total debt (mrq) 14.9B
Total Debt/Equity (mrq) 276.2
Current ratio (mrq) 3.13%
Book value per share (mrq) 2.02
Cash Flow
Cash flow statement 3.59B
Levered free cash flow (LFCF) 1.03B
